
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd is experiencing a favorable trajectory in its utilization rates, having increased over 50% since the establishment of its investment strategy, indicating strong demand for its Deep TMS technology. The recent FDA approval for the Neurolief Proliv™Rx device paves the way for enhanced pricing and market opportunities, while strategic investments are anticipated to drive accelerated revenue growth. Furthermore, the company is enjoying increased receptivity to pay-per-use models and potential growth in the neurologist specialist prescriber segment, which positions it favorably in the evolving mental health treatment landscape.
Bears say
BrainsWay Ltd faces several significant risks that contribute to a negative outlook on its stock. First, there is a concern regarding the slower-than-expected adoption of its Deep TMS systems, which could hinder revenue growth. Additionally, challenges related to expanding reimbursement and market access, as well as the inability to progress in other clinical indications, further exacerbate financial uncertainties, alongside the potential for long-term dilution impacting current shareholders.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares